MESOBLAST LIMITED (MSB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

MSB - MESOBLAST LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -2.15
Index: ASX300 | ALL-ORDS

Mesoblast is a Melbourne-headquartered medical research company investigating stem cell treatments and allogenic cellular medicines. The company was founded and listed in 2004.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.485

21 Nov
2024

-0.090

OPEN

$1.58

-5.71%

HIGH

$1.59

4,697,277

LOW

$1.47

TARGET
$1.40 -5.7% downside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
MSB: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) - 10.6 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-13.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx9.0 M
Book Value Per Share xxxxxxxxxxxxxxx63.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-85.1 M
Net Profit Margin xxxxxxxxxxxxxxx-1,490.27 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-18.22 %
Return on Invested Capital xxxxxxxxxxxxxxx-15.03 %
Return on Assets xxxxxxxxxxxxxxx-13.37 %
Return on Equity xxxxxxxxxxxxxxx-18.22 %
Return on Total Capital xxxxxxxxxxxxxxx-9.83 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-85.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx25 M
Long Term Debt xxxxxxxxxxxxxxx153 M
Total Debt xxxxxxxxxxxxxxx178 M
Goodwill - Gross xxxxxxxxxxxxxxx201 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx94 M
Price To Book Value xxxxxxxxxxxxxxx1.57

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxxxxxxxx5.61 %
Cost of Goods Sold xxxxxxxxxxxxxxx24 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx75 M
Research & Development xxxxxxxxxxxxxxx39 M
Investments - Total xxxxxxxxxxxxxxx2 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

30/08/2024

1

Speculative Buy

$1.40

-5.72%

Mesoblast delivered an EBIT loss of -$56.2m in FY24, greater than forecast. Going forward direction hinges upon BLA approval for Remestemcel-L, which has been accepted for review by the US FDA and scheduled for January 2025, suggests Bell Potter.

This will allow for immediate release of product (brand name Ryoncil) to the market and, as Bell Potter notes, substantial revenue generation and an inevitable re-rating of the stock.

Speculative Buy rating and $1.40 target unchanged. The broker points out there is substantial debt accumulating on the balance sheet and approval of the product is needed to avoid further large dilution.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -10.55 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -7.69 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

MSB STOCK CHART

FNArena News on MSB

1
Next Week At A Glance – 7-11 Oct 2024

Oct 04 2024 - Weekly Reports
2
FNArena Corporate Results Monitor – 30-08-2024

Aug 30 2024 - Australia
3
April In Review: The Bond Market Roared

May 06 2024 - Australia
4
The Short Report – 21 Dec 2023

Dec 21 2023 - Weekly Reports
5
Dr Boreham’s Crucible: Paradigm Biopharmaceuticals

Nov 06 2023 - Small Caps

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps